Award
National Institute of Allergy and Infectious Diseases RFA-AI-23-059
A Novel RAD51-BRCA2 Complex Stabilizing Drug: A Medical Countermeasure for Mitigating Accidental Radiation Exposure
Recipient
Not specified
Award Amount
$583,468.00
Ceiling
$583,468.00
Awarded
September 16, 2025
Identifier
RFA-AI-23-059
Award for developing a drug to stabilize the RAD51-BRCA2 complex to mitigate accidental radiation exposure, funded by NIH.
Description
The project involves developing a small molecule drug targeting the BRCA2-RAD51 complex to mitigate radiation-induced tissue damage. It includes optimizing the drug regimen, elucidating the mechanism of action, and evaluating efficacy in mitigating gastrointestinal and cardiac toxicities. The award is funded by the NIH Office of the Director and the National Institute of Allergy and Infectious Diseases as part of a broader effort to develop medical countermeasures for accidental radiation exposure.